GABRD and neoplasm: Increased expression of GABRD was correlated with negative indicators of patient prognosis, including a decrease in months of progression-free survival (n = 78; Spearman r = −0.36; p = 2.8 × 10−3) and an increase in the occurrence of new neoplasm events following initial therapy (no new neoplasm: n = 34, avg ± SEM = 5.9 ± 0.3 log2 RSEM; new neoplasm: n = 35, avg ± SEM = 7.2 ± 0.2 log2 RSEM; unpaired t-test, p = 8.6 × 10−4).